FLGT Fulgent Genetics, Inc.
8-K Current Report
Filed: March 17, 2026
Health Care
Services-Medical LaboratoriesFulgent Genetics, Inc. (FLGT) 8-K current report filed with SEC EDGAR on March 17, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 2.01: Completion of Acquisition or Disposition of Assets
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 2.01 · Completion of Acquisition or Disposition of Assets
- • Combined cash consideration ~$56.9M ($13.5M for StrataDx equity + $43.4M for Bako assets), both deals closed March 17, 2026
- • APA covers dermatopathology, podiatric pathology, molecular diagnostics, and therapeutic products — direct bolt-on to Inform Diagnostics subsidiary
Item 7.01 · Regulation FD Disclosure
- • Fulgent Genetics (FLGT) and Consonance Capital Partners announced dual transaction closings: PSA (Purchase and Sale Agreement) and APA (Asset Purchase Agreement)
- • Joint closing signals completion of a significant asset transaction with Consonance, a healthcare-focused investment firm
Other Fulgent Genetics, Inc. 8-K Filings
Get deeper insights on Fulgent Genetics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.